Microbiome of Depression & Treatment Response to Citalopram
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the feasibility of developing a microbiome probe of
depression and to evaluate the microbiome change in a preliminary analysis of treatment
response (n=20) vs. non response (n=20) to the antidepressant citalopram. This study is a 12
week open trial that will enroll approximately 80 participants (anticipated 40 study
completers with paired biomarker data) with an episode of major depression, Bipolar I or
Bipolar II and 40 age- and sex-matched healthy controls.